Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 5Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1Adrenal Insufficiency 1

Interventions

fludarabine phosphate 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2treosulfan 1thymoglobulin 1ravulizumab 1X-Rays 1Whole-Body Irradiation 1Sirolimus 1Mycophenolic Acid 1Melphalan 1Etoposide 1Cyclosporine 1Cyclophosphamide 1Busulfan 1Bone Marrow Transplantation 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoglobinuria, Paroxysmal × ravulizumab × 90 days × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔